AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 291 min read$NTRA

Fesko John sold $2.1M of NTRA

Fesko John (PRESIDENT, CHIEF BUS. OFFICER) sold 6,517 shares of Natera, Inc. (NTRA) at $321.53 ($2.10M total) on 2026-08-10 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Fesko John
Published Aug 29, 2026, 1:35 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 29, 2026, 1:35 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$NTRA
Bearish
medium confidence
Mentioned
$NTRA
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRABearishLow
01

Why it matters

The disclosed sale may influence short‑term sentiment but the company’s fundamentals remain unchanged.

02

Market read

First‑hand insider sale provides fresh data for traders monitoring NTRA.

03

What to watch

The insider retains a large stake (197,257 shares) indicating continued commitment.

Relevance 5/10Novelty 8/10Timing: after‑hours filing on 2026‑08‑28

Background

SEC Form 4 filing discloses an insider transaction for Natera, Inc.

Company-level read

Ticker impact

$NTRABearishMedium confidence
Context

President and COO John Fesko sold 6,517 Natera shares for $2.1M via a 10b5‑1 plan.

Expected impact

Potential short‑term downside pressure, 1‑2% dip if market reacts.

Evidence & confidence

Sale size is modest but the insider is a senior officer; 10b5‑1 plans soften the signal but still warrant caution.

Market effects

Sector

May raise concerns for other reproductive‑health biotech stocks.

Regional

Limited to US biotech sector.

Global

Minimal global effect.

Counterpoint

What could challenge this read

The sale could be routine portfolio rebalancing under a pre‑arranged plan, not a lack of confidence.

Key entities

  • Company
    Natera, Inc.

    US‑listed genetic testing company (ticker NTRA).

  • Executive
    John Fesko

    President and Chief Business Officer of Natera.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

NTRA insider trading history →

Related articles

SEP 9
$NTRAMed

Jim Cramer Calls Natera (NTRA) “a Promising Story”

Natera (NTRA) reported Q2 revenue of $752.8M, up 37.7% YoY, and raised its 2026 revenue forecast. Jim Cramer called it a promising precision medicine platform but advised waiting for a pullback due to valuation concerns. The company faces competition and regulatory risks, with a net loss of $67M in Q2.

yahoo.com2 min
SEP 2
$MRNAHighAI 8/10

Why Moderna's Cancer Vaccine Matters To Investors

Moderna (MRNA) and Merck (MRK) reported successful late-stage trial results for a personalized mRNA cancer vaccine targeting melanoma, reducing recurrence risk by 49%. The treatment relies on technologies from Illumina (ILMN), Danaher (DHR), and others. Moderna's stock surged 176.97% on the news, highlighting the shift toward individualized therapies in oncology.

etfdb.com3 min
AUG 24
$NTRAMed

Billionaire Stanley Druckenmiller Bought Amazon and Alphabet in Q2. But His Single Biggest Holding Is Neither of Them -- and It's Not Nvidia Either.

Billionaire investor Stanley Druckenmiller's largest Q2 holding was Natera (NTRA), a genetic testing company, not Amazon or Alphabet. Natera reported Q2 2026 revenue of $752.8M, up 39% YoY, and raised full-year guidance to $2.85B-$2.91B. The company's Signatera cancer detection test is a key growth driver, with FDA, PMDA, and EU approvals.

fool.com2 min